These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 31337673

  • 1. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
    Xue M, Li T, Wang Y, Chang Y, Cheng Y, Lu Y, Liu X, Xu L, Li X, Yu X, Sun B, Chen L.
    Clin Sci (Lond); 2019 Aug 15; 133(15):1705-1720. PubMed ID: 31337673
    [Abstract] [Full Text] [Related]

  • 2. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase) - cGMP (cyclic guanosine monophosphate) - PKG (protein kinase G) pathway.
    Chen L, Zhou X, Deng Y, Yang Y, Chen X, Chen Q, Liu Y, Fu X, Kwan HY, You Y, Jin W, Zhao X.
    J Ethnopharmacol; 2023 Jan 10; 300():115705. PubMed ID: 36099983
    [Abstract] [Full Text] [Related]

  • 3. Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function.
    Wang J, Huang X, Liu H, Chen Y, Li P, Liu L, Li J, Ren Y, Huang J, Xiong E, Tian Z, Dai X.
    Oxid Med Cell Longev; 2022 Jan 10; 2022():1122494. PubMed ID: 35585884
    [Abstract] [Full Text] [Related]

  • 4. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L.
    Cardiovasc Diabetol; 2019 Feb 02; 18(1):15. PubMed ID: 30710997
    [Abstract] [Full Text] [Related]

  • 5. The vasodilatory effect of sulfur dioxide via SGC/cGMP/PKG pathway in association with sulfhydryl-dependent dimerization.
    Yao Q, Huang Y, Liu AD, Zhu M, Liu J, Yan H, Zhang Q, Geng B, Gao Y, Du S, Huang P, Tang C, Du J, Jin H.
    Am J Physiol Regul Integr Comp Physiol; 2016 Jun 01; 310(11):R1073-80. PubMed ID: 27009048
    [Abstract] [Full Text] [Related]

  • 6. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J, Klinkhammer BM, Droste P, Kappel B, Haj-Yehia E, Maxeiner S, Artati A, Adamski J, Boor P, Schütt K, Lopaschuk GD, Verma S, Marx N, Lehrke M.
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug 01; 1866(8):165807. PubMed ID: 32353614
    [Abstract] [Full Text] [Related]

  • 7. Dioscin Attenuates Myocardial Damages in Diabetic Rats maybe by Regulating NO-sGC-cGMP-PKG Pathway.
    Wei Q, Zhu T, Xiao X, Sun L, Zhang Z, Huang T.
    Ann Clin Lab Sci; 2019 Jan 01; 49(1):97-104. PubMed ID: 30814084
    [Abstract] [Full Text] [Related]

  • 8. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
    Trang NN, Chung CC, Lee TW, Cheng WL, Kao YH, Huang SY, Lee TI, Chen YJ.
    Int J Mol Sci; 2021 Jan 25; 22(3):. PubMed ID: 33503985
    [Abstract] [Full Text] [Related]

  • 9. Polygonatum sibiricum (Huang Jing) polysaccharide reduces diabetic cardiomyopathy through increasing cyclic guanosine monophosphate-protein kinase G signaling in diabetic mice.
    Lei S, Lu X, Yan L, Liu T, Niu Y, Yu J.
    J Diabetes Investig; 2024 Jul 25; 15(7):823-834. PubMed ID: 38553792
    [Abstract] [Full Text] [Related]

  • 10. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M, Kröller-Schön S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm P, Mader M, Zinßius E, Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari SP, Mayoux E, Münzel T, Daiber A.
    PLoS One; 2014 Jul 25; 9(11):e112394. PubMed ID: 25402275
    [Abstract] [Full Text] [Related]

  • 11. Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.
    Matei AE, Beyer C, Györfi AH, Soare A, Chen CW, Dees C, Bergmann C, Ramming A, Friebe A, Hofmann F, Distler O, Schett G, Distler JHW.
    Ann Rheum Dis; 2018 Mar 25; 77(3):459. PubMed ID: 29311148
    [Abstract] [Full Text] [Related]

  • 12. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes.
    Kadosaka T, Watanabe M, Natsui H, Koizumi T, Nakao M, Koya T, Hagiwara H, Kamada R, Temma T, Karube F, Fujiyama F, Anzai T.
    Am J Physiol Heart Circ Physiol; 2023 Mar 01; 324(3):H341-H354. PubMed ID: 36607794
    [Abstract] [Full Text] [Related]

  • 13. Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.
    Cortese-Krott MM, Mergia E, Kramer CM, Lückstädt W, Yang J, Wolff G, Panknin C, Bracht T, Sitek B, Pernow J, Stasch JP, Feelisch M, Koesling D, Kelm M.
    Redox Biol; 2018 Apr 01; 14():328-337. PubMed ID: 29024896
    [Abstract] [Full Text] [Related]

  • 14. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S.
    Cardiovasc Diabetol; 2014 Oct 26; 13():148. PubMed ID: 25344694
    [Abstract] [Full Text] [Related]

  • 15. Magnesium lithospermate B, an active extract of Salvia miltiorrhiza, mediates sGC/cGMP/PKG translocation in experimental vasospasm.
    Chang CZ, Wu SC, Kwan AL.
    Biomed Res Int; 2014 Oct 26; 2014():272101. PubMed ID: 24804208
    [Abstract] [Full Text] [Related]

  • 16. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.
    Mátyás C, Németh BT, Oláh A, Hidi L, Birtalan E, Kellermayer D, Ruppert M, Korkmaz-Icöz S, Kökény G, Horváth EM, Szabó G, Merkely B, Radovits T.
    Cardiovasc Diabetol; 2015 Oct 31; 14():145. PubMed ID: 26520063
    [Abstract] [Full Text] [Related]

  • 17. Protein Kinase G Activation Reverses Oxidative Stress and Restores Osteoblast Function and Bone Formation in Male Mice With Type 1 Diabetes.
    Kalyanaraman H, Schwaerzer G, Ramdani G, Castillo F, Scott BT, Dillmann W, Sah RL, Casteel DE, Pilz RB.
    Diabetes; 2018 Apr 31; 67(4):607-623. PubMed ID: 29301852
    [Abstract] [Full Text] [Related]

  • 18. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
    Steven S, Oelze M, Hanf A, Kröller-Schön S, Kashani F, Roohani S, Welschof P, Kopp M, Gödtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, Münzel T, Daiber A.
    Redox Biol; 2017 Oct 31; 13():370-385. PubMed ID: 28667906
    [Abstract] [Full Text] [Related]

  • 19. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D, Pabel S, Tian Y, Lódi M, Herwig M, Carrizzo A, Zhazykbayeva S, Kovács Á, Fülöp GÁ, Falcão-Pires I, Reusch PH, Linthout SV, Papp Z, van Heerebeek L, Vecchione C, Maier LS, Ciccarelli M, Tschöpe C, Mügge A, Bagi Z, Sossalla S, Hamdani N.
    Cardiovasc Res; 2021 Jan 21; 117(2):495-507. PubMed ID: 32396609
    [Abstract] [Full Text] [Related]

  • 20. The bradykinin-cGMP-PKG pathway augments insulin sensitivity via upregulation of MAPK phosphatase-5 and inhibition of JNK.
    Frigolet ME, Thomas G, Beard K, Lu H, Liu L, Fantus IG.
    Am J Physiol Endocrinol Metab; 2017 Sep 01; 313(3):E321-E334. PubMed ID: 28679626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.